ESCROW AGREEMENTEscrow Agreement • June 22nd, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Delaware
THIS ESCROW AGREEMENT, dated as of __________, 2018 (the “Escrow Agreement”), is by and between SI Securities, LLC (“SI Securities”), 20/20 GeneSystems, Inc., a Delaware corporation (“Issuer”), and The Bryn Mawr Trust Company of Delaware (“BMTC DE”), a Delaware entity, as Escrow Agent hereunder (“Escrow Agent”). Capitalized terms used herein, but not otherwise defined, shall have the meaning set forth in that certain Issuer Agreement, dated as of April 16, 2018, by and between Issuer and SI Securities executed prior hereto (the “Issuer Agreement”).
SUBSCRIPTION AGREEMENTSubscription Agreement • June 22nd, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Delaware
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.
October 26, 2017Option Agreement to License and Commercialize Pan-Cancer Test Algorithm • June 22nd, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories
Pursuant to discussions between the Parties, the Option Agreement to License and Commercialize Pan-Cancer Test Algorithm (“Agreement”) between CGMH and 20/20 GeneSystems shall be amended as follows:
SI Securities, LLCOffering Agreement • June 22nd, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • New York
CANCER EARLY DETECTION ALGORITHM DEVELOPMENT COLLABORATION AGREEMENTDevelopment Collaboration Agreement • June 22nd, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Maryland
THIS DEVELOPMENT COLLABORATION AGREEMENT (this “Agreement”) having an effective date of February 26, 2016 (“Effective Date”), is entered into by and between National Foundation for Cancer Research, Inc., 4600 East West Highway, Suite 525, Bethesda, Maryland 20814 (“NFCR”) and 20/20 GenesyStems, Inc., 9430 Key West Avenue, Rockville, MD 20850 (“20/20”).
Option Agreement to License and Commercialize Pan-Cancer Test Algorithm Not binding until signed by authorized representatives of both parties. This draft document does not require either party to enter into an agreement.Option Agreement • June 22nd, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories
THIS OPTION AGREEMENT (“Agreement”) is entered into by and between Chang Gung Memorial Hospital, Linkou (“CGMH”) of Taiwan, a foundation organized and existing under the laws of Taiwan, having an address at No. 5, Fuxing St., Guishan Dist., Taoyuan City 333, Taiwan (R.O.C.), (“CGMH”), and 20/20 GeneSystems, a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 9430 Key West Avenue, Suite 100, Rockville, MD, (“20/20”) as of the Effective Date.
